FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Human Drugs

CDER Updates Rare Disease Efforts

A CDER online post updates the Centers efforts to support rare disease drug development, particularly through data sharing initiatives that are import...

Human Drugs

GC Pharma Complete Response on Immune Globulin

FDA issues South Korea-based GC Pharma a complete response letter on its BLA for GC5107 (immune globulin intravenous (human), 10% Liquid) because the ...

Federal Register

Guide on Timely Product Recalls

Federal Register notice: FDA makes available a final guidance entitled Initiation of Voluntary Recalls Under 21 CFR Part 7, Subpart C.

Federal Register

FDA Debars George Kuiper for 5 Years

Federal Register notice: FDA debars George Kuiper for a period of five years from importing or offering for import any drug into the U.S. due to felon...

Medical Devices

DexCom Breakthrough Status for Glucose Monitor

FDA grants DexCom a breakthrough device designation for its Dexcom real-time continuous glucose monitoring system for use in the hospital setting.

Human Drugs

Senators Ask CMS Not to Hurt Alzheimers Drug Access, Research

Sens. Collins and Capito ask the Centers for Medicare and Medicaid Services to ensure that its national coverage decision on Aduhelm does not restrict...

Human Drugs

FDA Extends Review of TG Therapeutics Submissions

FDA extends by three months its review of a TG Therapeutics BLA and supplemental NDA for ublituximab in combination with Ukoniq (umbralisib), indicate...

Human Drugs

Median Seeks FDA Input on iBiopsy Regulatory Pathway

Median Technologies files a 513(g) submission seeking FDA guidance on the best path to market for its iBiopsy Lung Cancer Screening Artificial Intelli...

Medical Devices

Circa Scientific Esophageal Temperature Probe Cleared

FDA clears a Circa Scientific 510(k) for its S-CATH M Esophageal Temperature Probe which can be visualized on 3D cardiac mapping systems.

Human Drugs

Civica Planning for Affordable Insulins

Civica says it will develop and manufacture three insulin biosimilars to be sold at a lower price than current products.